Composite reagent for screening early-stage oral intima cell disease and application method thereof

Abstract

The invention discloses a composite reagent for screening early-stage oral intima cell diseases, which comprises: toluidine blue used as a biochemical reagent of the detection reagent, and acetic acid used as an auxiliary reagent of the detection reagent, wherein the concentration of the toluidine blue solution is 0.2-2%, and the concentration of the acetic acid solution is 0.01-5%. The invention also discloses an application method of the composite reagent for screening early-stage oral intima cell diseases, which is characterized in that the method comprises the following steps: firstly gargling with acetic acid for 1-2 min, then gargling with a mixed solution of toluidine blue and acetic acid for 1-2 min, and finally gargling with acetic acid for 1-2 min, wherein the ratio of toluidine blue and acetic acid in the mixed solution is 1:0.5-1.

Description

technical field [0001] The invention relates to the field of biochemistry, in particular to a clinical combination reagent for screening early-stage lesions of oral endometrial cells and a use method thereof. Background technique [0002] There are many kinds of lesions of the oral lining, among which oral cancer is an important and serious lesion of the oral lining, and it is also one of the common malignant tumors. In China, oral cancer accounts for 1.5% to 5.6% of the incidence of systemic malignant tumors, and the 5-year survival rate of oral cancer is only about 50%. The early oral cancer can be cured, but the advanced stage has a poor prognosis. Therefore, early diagnosis is the key to improving the survival rate and quality of life of patients. At present, in the medical field, the pathological mechanism of oral lining is still not completely clear, especially the development process from normal cells to cancer cells. People have also been working on the possibility...

AI Technical Summary

Problems solved by technology

[0003] At present, there are two categories of high-risk early lesion detection in the oral cavity: the first category is: invasive technology, that is, the method of histopathology using slice smears, which need to select cell tissue samples from the lesion and observe them under a microscope Lesions are easy to miss, and there are many factors of human judgment. The diagnostic effect is relatively poor, and it can only be used for the diagnosis of middle and late lesions.

The second category is: non-invasive techniques, mainly including exfoliated cytology, traditional toluidine blue staining and detection of hematoporphyrin derivatives, exfoliated cytology, a method started by Montgonony in 1951, using Exfoliated cells are used for intraoral detection, but the false positive of this method is very high, so it will not be used much later

However, due to its high false positive rate, it was not approved by the FDA in the United States

The accuracy of this method for the diagnosis of intraoral cancer is relatively high, and the operation is relatively simple, but the false positive rate is too high, so it cannot be applied well

In the 1980s, there was also a method of using hematoporphyrin derivatives to detect intraoral lesions, but due to relatively high requirements for equipment, many influencing factors, and high false negatives, it was gradually discontinued. up